CCND1 and neoplasm: Its mechanisms of action include the inhibition of the PI3K/AKT signaling pathway mediated by bone morphogenetic protein 7 (BMP-7), the reduction of proteins associated with tumor cell survival (such as Cyclin D1 and c-Myc), and the regulation of the cell cycle, thereby achieving anti-proliferative effects.